BCL3 and ovarian carcinoma: Although Bcl3 was first identified in patients with chronic lymphocytic leukemia [64], its increased expression has been demonstrated in many types of hematological malignancies [82,83,84,85,86,87,88], as well as in solid tumors, including ovarian cancer, hepatocellular and nasopharyngeal carcinoma and colorectal, cervical, breast and prostate cancers [47,71,78,79,89,90,91,92,93].